Canaccord lowered the firm’s price target on Guardant Health to $30 from $45 and keeps a Buy rating on the shares. The firm believes the recent selloff has provided an attractive opportunity to accumulate shares of the companey with potential catalysts and notes management could share updates related to their strategies for targeting focused markets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health assumed with a Buy at Craig-Hallum
- FDA Advisory Panel review of Guardant Health Shield Blood Test on May 23
- Guardant Health to present data on epigenomics at 2024 AACR meeting
- Canaccord positive on Exact, Guardant after Freenome data
- Exact Sciences, Guardant rally after Freenome colorectal cancer test results